{"id":"NCT00099268","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy","officialTitle":"A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2004-12-10","resultsPosted":"2011-03-08","lastUpdate":"2012-04-23"},"enrollment":747,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Carbidopa/levodopa/entacapone","otherNames":["Stalevo"]},{"type":"DRUG","name":"Immediate release carbidopa/levodopa","otherNames":["Sinemet"]}],"arms":[{"label":"Carbidopa/levodopa/entacapone","type":"EXPERIMENTAL"},{"label":"Immediate release carbidopa/levodopa","type":"ACTIVE_COMPARATOR"}],"summary":"The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.","primaryOutcome":{"measure":"Time to First Occurrence of Dyskinesia","timeFrame":"Treatment duration for an individual patient varied between a minimum of 134 weeks for those patients recruited last and a maximum of 208 weeks for those patients recruited first","effectByArm":[{"arm":"Carbidopa/Levodopa/Entacapone","deltaMin":90.7,"sd":47.9},{"arm":"Carbidopa/Levodopa","deltaMin":117.1,"sd":51.5}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":73,"countries":["United States","Austria","Belgium","Canada","Finland","France","Germany","Greece","Italy","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["20582993"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":373},"commonTop":["Nausea","Depression","Dizziness","Back pain","Insomnia"]}}